Stockreport

Ocugen: Downgrading After OCU410 Data Release [Seeking Alpha]

Ocugen, Inc.  (OCGN) 
PDF Preliminary phase 2 ArMaDa data showed a 46% reduction in lesion growth, but lacked dose-dependent efficacy and had a small sample size. Key catalysts include final A [Read more]